Metagenomic next-generation sequencing for the diagnosis of neurobrucellosis
Future Microbiology · 2024
DOI: 10.2217/fmb-2023-0177 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Microbiology, 2024. Verfasst von Wen Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Metagenomics, Brucellosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Discipline Promotion Project of Xijing Hospital.
Abstract (Originalsprache)
Objective
This study investigates the application of metagenomic next-generation sequencing (mNGS) in the diagnosis of neurobrucellosis (NB).
Methods
We retrospectively analyzed patients diagnosed with NB who underwent cerebrospinal fluid (CSF) mNGS testing in Xijing Hospital from 2015 to 2021.
Results
Among the 20 individuals included in the study, the serum rose bengal test was positive in 11 out of 16 cases, serum agglutination test was positive in 13 out of 16 cases, CSF culture was positive in 6 out of 11 cases, and CSF mNGS tests were positive in 18 out of 20 cases.
Conclusion
CSF mNGS demonstrates superior sensitivity; therefore, it is recommended to collect CSF for mNGS testing prior to antibiotic therapy when NB is suspected. Neurobrucellosis (NB) is a disease of the nervous system caused by a type of bacteria called Brucella. It is rare, serious and manifests inconsistently, making it hard to diagnose. Metagenomic next-generation sequencing (mNGS) is a new way to detect disease-causing bacteria by looking at their genetic material. mNGS is fast, accurate and covers a wide range of disease-causing bacteria. We looked back at patients diagnosed with NB at Xijing Hospital between 2015 and 2021 and tested samples of the fluid surrounding the brain and the spinal cord, called cerebrospinal fluid (CSF), by mNGS. A total of 20 patients were included in the study. Compared with the traditional methods, mNGS of CSF samples showed advantages in diagnosing NB. However, antibiotics may affect the results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
- Department of Neurology, Ordnance Industry No. 521 Hospital, Xi'an, China.
Förderung
- Discipline Promotion Project of Xijing Hospital
Zitieren
APA
Li, W., He, Y., Li, Y., Li, X., Bian, T., Liu, T., Liu, X., & Jiang, W. (2024). Metagenomic next-generation sequencing for the diagnosis of neurobrucellosis. Future Microbiology. https://doi.org/10.2217/fmb-2023-0177
Vancouver
Li W, He Y, Li Y, Li X, Bian T, Liu T, et al. Metagenomic next-generation sequencing for the diagnosis of neurobrucellosis. Future Microbiology. 2024. doi:10.2217/fmb-2023-0177
BibTeX
@article{Li2024,
author = {Li, Wen and He, Ying and Li, Yanyan and Li, Xiaona and Bian, Ting and Liu, Tingting and Liu, Xuedong and Jiang, Wen},
title = {Metagenomic next-generation sequencing for the diagnosis of neurobrucellosis},
journal = {Future Microbiology},
year = {2024},
doi = {10.2217/fmb-2023-0177}
}
EUVIMED